PARP-inhibitors: A New Generation of Cancer Drugs

First of new generation of cancer drugs granted European approval

A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.

[KGunTV]

The point in understanding if somebody really knows what he is talking about is, that he is able to explain it in a ridiculously easy way, so that everybody can understand it. This in turn makes this Prof., a real man understanding what he is doing.

[Amiralbahrami]

0:34 Please correct me if I'm wrong, on the picture we see 1 chromosome which consists of 2 sister chromatids and they should be identical, BRCAm and BRCAwt should be pictured on 2 homologous chromosomes? Thanks in advance

[matthewgrumbling]

A very clear and succinct explanation. Thanks.

[russelmiller]

Yes, a typical example of the inhibitors in this line is Olaparib. It selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks. PARP inhibition also showed potential in other aspects like enhancing the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance.

[GoTurbo]

First! Also, this is a very amazing breakthrough for human civilization.